Literature DB >> 10735626

Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer.

M Elleder1, A Chlumská, J Hyánek, H Poupĕtová, J Ledvinová, S Maas, P Lohse.   

Abstract

Few cases of asymptomatic cholesteryl ester storage disease (CESD) due to low enzymatic activity of human lysosomal acid lipase/cholesteryl ester hydrolase (hLAL) have been reported thus far in adults Here, we describe a 51-year-old man with a long clinical history of mixed hyperlipoproteinemia and severe premature atherosclerosis, but with no signs of hepatomegaly, liver dysfunction, or splenomegaly. The disease was discovered by chance in a biopsy performed because of suspected liver cancer (proven to be a cholangiocarcinoma). Residual hLAL activity in peripheral leukocytes was determined to be 6% of control values. DNA sequence and restriction fragment length polymorphism analysis demonstrated that the patient was a compound heterozygote for the prevalent CESD exon 8 splice site mutation (G934A) and the deletion of a C (nucleotide 673, 674, or 675) in exon 6 of the hLAL gene, resulting in premature termination of protein translation at residue 195. The patient died of liver failure as a consequence of extensive tumor infiltration at age 52. Lipid analysis revealed moderate cholesteryl ester storage in the liver and in the suprarenal cortex, and massive accumulation in the testicular histiocytes and Leydig cells, resulting in a pronounced secondary atrophy of the seminiferous tubules. Our case study demonstrates that hepatomegaly is an inconstant feature, even in CESD patients compound heterozygous for a Wolman mutation which results in complete loss of hLAL enzymic activity. It also highlights the need to be aware of this condition as it may be underdiagnosed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10735626     DOI: 10.1016/s0168-8278(00)80407-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  18 in total

1.  Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease.

Authors:  S Decarlis; C Agostoni; F Ferrante; S Scarlino; E Riva; M Giovannini
Journal:  J Inherit Metab Dis       Date:  2009-02-15       Impact factor: 4.982

2.  Severe chronic diarrhea and weight loss in cholesteryl ester storage disease: a case report.

Authors:  Uta Drebber; Matthias Andersen; Hans U Kasper; Peter Lohse; Manfred Stolte; Hans P Dienes
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 3.  Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult.

Authors:  Hemant Chatrath; Steven Keilin; Bashar M Attar
Journal:  Dig Dis Sci       Date:  2008-05-14       Impact factor: 3.199

4.  Orthotopic liver transplantation in an adult with cholesterol ester storage disease.

Authors:  Graeme K Ambler; Matthew Hoare; Rebecca Brais; Ashley Shaw; Andrew Butler; Paul Flynn; Patrick Deegan; William J H Griffiths
Journal:  JIMD Rep       Date:  2012-07-24

Review 5.  The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency.

Authors:  Angelika L Erwin
Journal:  Therap Adv Gastroenterol       Date:  2017-04-26       Impact factor: 4.409

Review 6.  Genetics of familial hypercholesterolemia.

Authors:  Ariel Brautbar; Emili Leary; Kristen Rasmussen; Don P Wilson; Robert D Steiner; Salim Virani
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

7.  Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups.

Authors:  Stuart A Scott; Benny Liu; Irina Nazarenko; Suparna Martis; Julia Kozlitina; Yao Yang; Charina Ramirez; Yumi Kasai; Tommy Hyatt; Inga Peter; Robert J Desnick
Journal:  Hepatology       Date:  2013-07-29       Impact factor: 17.425

Review 8.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26

9.  Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency.

Authors:  Vassili Valayannopoulos; Vera Malinova; Tomas Honzík; Manisha Balwani; Catherine Breen; Patrick B Deegan; Gregory M Enns; Simon A Jones; John P Kane; Eveline O Stock; Radhika Tripuraneni; Stephen Eckert; Eugene Schneider; Gavin Hamilton; Michael S Middleton; Claude Sirlin; Bruce Kessler; Christopher Bourdon; Simeon A Boyadjiev; Reena Sharma; Chris Twelves; Chester B Whitley; Anthony G Quinn
Journal:  J Hepatol       Date:  2014-06-30       Impact factor: 25.083

10.  Hepatocyte-Specific Expression of Human Lysosome Acid Lipase Corrects Liver Inflammation and Tumor Metastasis in lal(-/-) Mice.

Authors:  Hong Du; Ting Zhao; Xinchun Ding; Cong Yan
Journal:  Am J Pathol       Date:  2015-07-26       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.